Cargando…

In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy

Regardless of the recent advances in cytotoxic therapies, 30% of children diagnosed with medulloblastoma. succumb to the disease. Therefore, novel therapeutic approaches are warranted. Here we demonstrate that Pazopanib a clinically approved multi-kinase angiogenesis inhibitor (MKI) inhibits prolife...

Descripción completa

Detalles Bibliográficos
Autores principales:	Craveiro, Rogerio B., Ehrhardt, Michael, Holst, Martin I., Pietsch, Thorsten, Dilloo, Dagmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2014
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4196191/ https://www.ncbi.nlm.nih.gov/pubmed/25216529

Ejemplares similares

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy
por: Ehrhardt, Michael, et al.
Publicado: (2014)

The PI3K inhibitor pictilisib and the multikinase inhibitors pazopanib and sorafenib have an impact on Rac1 level and migration of medulloblastoma in vitro
por: Schoen, Leonie F., et al.
Publicado: (2022)

The FDA approved PI3K inhibitor GDC‐0941 enhances in vitro the anti‐neoplastic efficacy of Axitinib against c‐myc‐amplified high‐risk medulloblastoma
por: Ehrhardt, Michael, et al.
Publicado: (2018)

The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition
por: Craveiro, Rogerio B, et al.
Publicado: (2017)

Improved Glycemic Control With the Multi-Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Böhm, Steffen, et al.
Publicado: (2010)

Downregulation of 14q32 microRNAs in Primary Human Desmoplastic Medulloblastoma
por: Lucon, Danielle Ribeiro, et al.
Publicado: (2013)

The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib
por: Wilding, Christopher P, et al.
Publicado: (2019)

Gray Hair Associated with the Multitargeted Receptor Tyrosine Kinase Inhibitor Pazopanib
por: Yun, Hwan-Jung, et al.
Publicado: (2015)

Pazopanib, a promising option for the treatment of aggressive fibromatosis
por: Szucs, Zoltan, et al.
Publicado: (2017)

Medulloblastoma stem cells: Promising targets in medulloblastoma therapy
por: Huang, Guo‐Hao, et al.
Publicado: (2016)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Targeting EpCAM by a Bispecific Trifunctional Antibody Exerts Profound Cytotoxic Efficacy in Germ Cell Tumor Cell Lines
por: Schönberger, Stefan, et al.
Publicado: (2020)

Pazopanib, a novel multi-kinase inhibitor, shows potent antitumor activity in colon cancer through PUMA-mediated apoptosis
por: Zhang, Lingling, et al.
Publicado: (2016)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2018)

The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma
por: Shroff, Rachna T, et al.
Publicado: (2017)

Brentuximab vedotin exerts profound antiproliferative and pro‐apoptotic efficacy in CD30‐positive as well as cocultured CD30‐negative germ cell tumour cell lines
por: Schönberger, Stefan, et al.
Publicado: (2017)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
por: Booth, Laurence, et al.
Publicado: (2019)

The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo
por: Booth, Laurence, et al.
Publicado: (2017)

Tyrosine Kinase Inhibitor Pazopanib Inhibits Platelet Procoagulant Activity in Renal Cell Carcinoma Patients
por: Tullemans, Bibian M. E., et al.
Publicado: (2018)

L-4, a Well-Tolerated and Orally Active Inhibitor of Hedgehog Pathway, Exhibited Potent Anti-tumor Effects Against Medulloblastoma in vitro and in vivo
por: Zhu, Mingfei, et al.
Publicado: (2019)

A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis
por: Fauster, A, et al.
Publicado: (2015)

Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models()()()
por: Li, Haifu, et al.
Publicado: (2014)

Computational discovery and experimental verification of tyrosine kinase inhibitor pazopanib for the reversal of memory and cognitive deficits in rat model neurodegeneration
por: Yang, Yongliang, et al.
Publicado: (2015)

Sunitinib or Pazopanib: Is There Any Difference Between Tyrosine Kinase Inhibitors in the Pre-Nivolumab Setting in Metastatic Renal Cell Carcinoma?
por: Ucar, Gokhan, et al.
Publicado: (2020)

MBRS-02. BET BROMODOMAIN PROTEIN-KINASE INHIBITOR COMBINATIONS FOR THE TREATMENT OF MEDULLOBLASTOMA
por: Ayad, Nagi, et al.
Publicado: (2020)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature
por: Deguchi, Shoichi, et al.
Publicado: (2017)

Pazolimus: pazopanib plus sirolimus following progression on pazopanib, a retrospective case series analysis
por: Katz, D., et al.
Publicado: (2016)

The anti-angiogenic tyrosine kinase inhibitor Pazopanib kills cancer cells and disrupts endothelial networks in biomimetic three-dimensional renal tumouroids
por: Stamati, Katerina, et al.
Publicado: (2020)

Combination of Ribociclib with BET-Bromodomain and PI3K/mTOR Inhibitors for Medulloblastoma Treatment In Vitro and In Vivo
por: Jonchere, Barbara, et al.
Publicado: (2023)

Pazopanib diminishes non-small cell lung cancer (NSCLC) growth and metastases in vivo
por: Zhao, Honglin, et al.
Publicado: (2015)

ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside
por: Zhou, Jianbiao, et al.
Publicado: (2009)

Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma
por: Chan, Tiffany S Y, et al.
Publicado: (2021)

Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience
por: Frezza, Anna Maria, et al.
Publicado: (2014)

Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth in vitro and in vivo
por: Lee, Seung Joon, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kgr1d1ffogm51i1399a9j61941